Suministro del principio activo denominado "BLINATUMOMAB 38,5 MCG VIAL POLVO INTRAVENOSA "para el Hospital Universitario de Gran Canaria Dr. Negrín.
TED · 440484-2026Award noticeawardedNo deadline given
Buyer
NameDirección Gerencia Hospital Universitario de Gran Canaria Doctor Negrín
CountryES
Published2026-06-26
Deadline—
Who already wins at this buyer
Firms with recorded awards from Dirección Gerencia Hospital Universitario de Gran Canaria Doctor Negrín in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| IPSEN PHARMA, S.A.U. | 1 | €595,637 | 2026-06-18 |
| SWEDISH ORPHAN BIOVITRUM S.L | 1 | €403,705 | 2026-05-27 |
| IPSEN PHARMA, S.A. | 1 | €396,028 | 2026-05-11 |
| MERCK SHARP & DOHME ESPAÑA, S.A. | 1 | €332,277 | 2026-05-11 |
| ROCHE FARMA, S.A. | 1 | €305,648 | 2026-07-13 |
CPV codes
33690000 Medical equipment & pharmaceuticalsDescription
El objeto del contrato viene determinado por el suministro del principio activo denominado "BLINATUMOMAB 38,5 MCGVIAL POLVO INTRAVENOSA " para el Hospital Universitario de Gran Canaria Dr. Negrín.Dicho objeto corresponde al código 33690000-3 (Medicamentos diversos), de la nomenclatura Vocabulario Común deContratos (CPV) de la Comisión Europea.
Similar tenders
Closest by meaning — across languages, via embeddings.